Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
Related Questions
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
What baseline visual testing, if any, do you recommend at diagnosis for patients with multiple sclerosis who deny visual complaints?
If a patient develops itching with their first dose of Tysabri despite pre-treatment, does this indicate that further cycles of Tysabri are contraindicated or do you continue Tysabri at the next cycle?
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
What is your approach to dosing rituximab in patients with multiple sclerosis?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
When do you start cyclophosphamide for the treatment of anti-NMDA receptor encephalitis?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
